This article is more than 5 years old. Information may no longer be current.

Darren K. McGuire, MD, MHSc, on the 3-year STAMPEDE trial results

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WASHINGTON — In this video, Darren K. McGuire, MD, MHSc, professor of internal medicine and Dallas Heart Ball Chair for research on heart disease in women at University of Texas Southwestern Medical Center, discussed 3-year data from the STAMPEDE trial, presented at the American College of Cardiology Scientific Sessions.

The trial included 150 obese patients with diabetes randomly assigned intensive medical therapy alone, Roux-en-Y gastric bypass with medical therapy or sleeve gastrectomy with medical therapy. HbA1c ≤6% was the primary endpoint of the study, and was achieved by significantly more patients in the gastric bypass and sleeve gastrectomy groups.

McGuire said that these results add to mounting evidence suggesting the importance of mechanical interventions for the reduction of obesity, but noted that the trial was not sufficiently powered to assess clinical outcomes. The long-term clinical impact on macrovascular and microvascular disease complications, he concluded, remain to be determined.